Latest Data for Factor XIa Inhibition: Time to Shift the Paradigm in Secondary Stroke Prevention?

In this activity, based on a recent live event, experts in stroke management explore newly presented evidence for Factor XIa (FXIa) inhibition, as well as guideline-directed best practices, for secondary stroke prevention. For the complete activity, including supporting material, please visit: www.peervoice.com/GWR861. Presented by: Mike Sharma, MD, MSc, FRCPC, Xin Cheng, MD, PhD, Emiliya Melkumova, MD, and Roland Veltkamp, MD. Learning Objectives: Evaluate efficacy and safety outcomes for Factor XIa (FXIa) inhibitors in the prevention of ischemic stroke following an acute non-cardioembolic ischemic stroke (NCIS) or high-risk transient ischemic attack (TIA); Identify patient-specific characteristics that may influence the efficacy or safety of FXIa inhibitors for secondary stroke prevention (SSP); Apply current guideline-directed best practices for the management of acute NCIS or high-risk TIA.